Neutropenia in a Patient Receiving Intravenous Immune Globulin
Overview
Authors
Affiliations
A child with Guillain-Barre syndrome treated with intravenous immune globulin (IVIG) developed neutropenia (absolute neutrophil count = 390), which resolved 3 days after completion of the therapy. Potential mechanisms for the development of neutropenia during the use of IVIG therapy are discussed. In this case, testing of the IVIG used revealed the presence of a high concentration of anti-neutrophil antibodies compared to other samples. It is recommended that white blood cell and neutrophil counts be monitored daily during the use of such therapy.
Intravenous immunoglobulin in neurological disease: a specialist review.
Wiles C, Brown P, Chapel H, Guerrini R, Hughes R, MARTIN T J Neurol Neurosurg Psychiatry. 2002; 72(4):440-8.
PMID: 11909900 PMC: 1737833. DOI: 10.1136/jnnp.72.4.440.
Human intravenous immunoglobulin (IVIG) preparations degranulate human neutrophils in vitro.
Teeling J, de Groot E, Eerenberg A, Bleeker W, van Mierlo G, Aarden L Clin Exp Immunol. 1998; 114(2):264-70.
PMID: 9822286 PMC: 1905117. DOI: 10.1046/j.1365-2249.1998.00697.x.
Anti-DNA and antiphospholipid antibodies in IVIG preparations: in vivo study in naive mice.
Krause I, Blank M, Shoenfeld Y J Clin Immunol. 1998; 18(1):52-60.
PMID: 9475354 DOI: 10.1023/a:1023239904856.